Tocilizumab has improved neurological symptoms in a patient with ICI-related steroid-refractory transverse myelitis with high levels of IL-6 in the CSF [138] and demonstrated efficacy in patients with ICI-mediated cerebritis [139]. The gene discussed is IL6; the disease is cerebritis.